Table 1.
Clinical Characteristics of the Patients.*
| Characteristic | Overall (N = 1362) |
MSK (N = 1076) |
Regensburg (N = 78) |
Duke (N = 142) |
Hokkaido (N = 66) |
|---|---|---|---|---|---|
| Age at HCT — yr | 52.9±13.0 | 53.6±12.8 | 51.3±11.7 | 50.6±13.2 | 49.1±14.5 |
| Male sex — no. (%) | 833 (61) | 650 (60) | 47 (60) | 99 (70) | 37 (56) |
| Disease — no. (%) | |||||
| Acute myeloid leukemia | 490 (36) | 373 (35) | 43 (55) | 42 (30) | 32 (48) |
| Myelodysplastic syndrome or myeloproliferative neoplasm | 264 (19) | 208 (19) | 8 (10) | 41 (29) | 7 (11) |
| Non-Hodgkin’s lymphoma | 229 (17) | 187 (17) | 12 (15) | 25 (18) | 5 (8) |
| Acute lymphoid leukemia | 128 (9) | 94 (9) | 6 (8) | 13 (9) | 15 (23) |
| Myeloma | 111 (8) | 97 (9) | 3 (4) | 10 (7) | 1 (2) |
| Chronic lymphocytic leukemia | 33 (2) | 30 (3) | 3 (4) | 0 | 0 |
| Hodgkin’s lymphoma | 31 (2) | 27 (3) | 0 | 3 (2) | 1 (2) |
| Chronic myeloid leukemia | 29 (2) | 23 (2) | 1 (1) | 4 (3) | 1 (2) |
| Aplastic anemia | 10 (1) | 5 (<1) | 2 (3) | 2 (1) | 1 (2) |
| Other† | 37 (3) | 32 (3) | 0 | 2 (1) | 3 (5) |
| Graft type — no. (%) | |||||
| Unmodified bone marrow | 113 (8) | 83 (8) | 11 (14) | 13 (9) | 6 (9) |
| Cord blood | 211 (15) | 178 (17) | 0 | 19 (13) | 14 (21) |
| T-cell–depleted PBSCs | 447 (33) | 447 (42) | 0 | 0 | 0 |
| Unmodified PBSCs | 591 (43) | 368 (34) | 67 (86) | 110 (77) | 46 (70) |
| Intensity of conditioning regimen — no. (%) | |||||
| Ablative | 771 (57) | 598 (56) | 10 (13) | 116 (82) | 47 (71) |
| Reduced intensity | 468 (34) | 367 (34) | 68 (87) | 14 (10) | 19 (29) |
| Nonmyeloablative | 123 (9) | 111 (10) | 0 | 12 (8) | 0 |
| HCT-CI‡ | 2.6±2.0 | 2.6±2.1 | 2.2±1.7 | 3.4±.7 | 1.6±1.7 |
| Follow-up of survivors — mo | |||||
| Median | 25.2 | 34.2 | 32.5 | 15.0 | 8.3 |
| Interquartile range | 12.8–49.9 | 15.5–56.5 | 26.0–44.4 | 5.8–23.5 | 4.5–12.9 |
A total of 79% of the patients in the overall study population were enrolled at Memorial Sloan Kettering Cancer Center (MSK), New York; 6% at University Medical Center, University Hospital Regensburg, Regensburg, Germany; 10% at Duke University Medical Center, Durham, North Carolina; and 5% at Hokkaido University Hospital, Sapporo, Japan. Additional details are provided in Tables S1 and S2 and in Figure S1. HCT denotes hematopoietic-cell transplantation, and PBSC peripheral-blood stem cell.
Diseases categorized as “other” included biphenotypic acute leukemia, natural killer–cell large granular lymphocyte leukemia, plasmacytoid dendritic-cell neoplasms, and nonmalignant hematologic disorders, including familial hemophagocytic lymphohistiocytosis, X-linked lympho-proliferative disease, and paroxysmal nocturnal hemoglobinuria.
In the hematopoietic-cell transplantation comorbidity index (HCT-CI), weighted scores for individual organ dysfunctions before transplantation are summed; scores range from 0 to a theoretical maximum of 26, with higher scores indicating a higher risk of death after transplantation.30